Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Brief Pharmacological Intervention in Experimental Radiation Nephropathy

J. E. Moulder, B. L. Fish and E. P. Cohen
Radiation Research
Vol. 150, No. 5 (Nov., 1998), pp. 535-541
DOI: 10.2307/3579870
Stable URL: http://www.jstor.org/stable/3579870
Page Count: 7
  • Read Online (Free)
  • Download ($10.00)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Brief Pharmacological Intervention in Experimental Radiation Nephropathy
Preview not available

Abstract

Brief postirradiation treatment with an angiotensin-converting enzyme (ACE) inhibitor has been shown to be effective in reducing the severity of radiation nephropathy in rats. The efficacy of brief treatment with an ACE inhibitor was shown to be greatest when the animals were young when irradiated and when the treatment was given 4 to 10 weeks after bone marrow transplantation (BMT). In further studies with a BMT nephropathy model, we have shown that brief treatment with an angiotensin II type I receptor antagonist (AII blocker) is even more effective than brief treatment with an ACE inhibitor. We have also shown that an NO synthase inhibitor, which exacerbated radiation nephropathy when given continuously, has no effect when given during the postirradiation interval when ACE inhibitors and AII blockers were most effective. Studies also showed that the loss of efficacy of brief treatment with increased age at irradiation parallels the decrease in radiosensitivity that occurs with increasing age at irradiation, but that this decrease in radiosensitivity is not sufficient to explain the loss of efficacy of brief treatment. These data indicate that the renin-angiotensin system is important in the expression of renal radiation injury, particularly between 4 and 10 weeks after irradiation.

Page Thumbnails

  • Thumbnail: Page 
535
    535
  • Thumbnail: Page 
536
    536
  • Thumbnail: Page 
537
    537
  • Thumbnail: Page 
538
    538
  • Thumbnail: Page 
539
    539
  • Thumbnail: Page 
540
    540
  • Thumbnail: Page 
541
    541